2. Academic Validation
  3. Nanomaterial Delivery Systems for mRNA Vaccines

Nanomaterial Delivery Systems for mRNA Vaccines

  • Vaccines (Basel). 2021 Jan 19;9(1):65. doi: 10.3390/vaccines9010065.
Michael D Buschmann 1,  Manuel J Carrasco 1,  Suman Alishetty 1,  Mikell Paige 2,  Mohamad Gabriel Alameh 3,  Drew Weissman 4
Affiliations

Affiliations

  • 1 Department of Bioengineering, George Mason University, 4400 University Drive, MS 1J7, Fairfax, VA 22030, USA.
  • 2 Department of Chemistry & Biochemistry, George Mason University, 4400 University Drive, Fairfax, VA 22030, USA.
  • 3 Perelman School of Medicine, University of Pennsylvania, 130 Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.
  • 4 Perelman School of Medicine, University of Pennsylvania, 410B Hill Pavilion, 380 S. University Ave, Philadelphia, PA 19104, USA.
PMID: 33478109 DOI: 10.3390/vaccines9010065
Abstract

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.

Keywords

SARS-CoV-2; ionizable lipid; lipid nanoparticle; mRNA; vaccine.

Figures
Products